FTSE MIB
33.308,77 -366,38 (-1,09%) Dow Jones
39.150,33 +15,57 (+0,04%) Nasdaq
17.689,36 -32,23 (-0,18%) Nikkei 225
38.596,47 -36,55 (-0,09%) Petrolio
82,34 +0,17 (+0,21%) Bitcoin EUR
60.265,34 +282,94 (+0,47%)
OCEA Jun 2024 3.500 put
| Chiusura precedente | 3,4000 |
| Aperto | N/D |
| Denaro | 1,8000 |
| Domanda | 3,5000 |
| Prezzo d'esercizio | 3,50 |
| Scadenza | 2024-06-21 |
| Min-Max giorno | 3,4000 - 3,4000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 1 |
GlobeNewswireOcean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients Worldwide
Providence, Rhode Island, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, and Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, today announced they have entered into a joint venture to accelerate and expand Virion’s clinical-stage program and pipeline, with the goal of finding cures for patients w
- GlobeNewswire
Updated: Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with Polar Multi-Strategy Master Fund
Providence, RI, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announces that the company and Polar Multi-Strategy Master Fund (Polar) entered into a Side Letter related to the Forward Purchase Agreement entered into in February 2023. The Side Letter provides for an $8.00 per share Reset Price which is intended to increase the circumstances under which Polar would remit funds to the company during the term of the agreement and lowers the “Seller VWAP Trigger Event” price
- GlobeNewswire
Ocean Biomedical Announces Loan Commitment from Largest Stockholder; Up to $10 Million
Providence, RI, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that it has entered into a non-binding term sheet with its largest stockholder, Poseidon Bio, LLC, majority owned by Dr. Chirinjeev Kathuria, for a proposed debt facility consisting of convertible promissory notes with a principal amount of up to $10 million. The promissory notes may be issued in one or more closings and Ocean Biomedical does not expect to draw the full amount at any one closi
